Case Report
Treatment of Chronic Myelomonocytic Leukemia with 5-Azacytidine: Case Reports
Table 1
Patients’ characteristics.
| | Patient 1 | Patient 2 | Patient 3 |
| | Basic information | | | |
| | Age at dg. (years) | 59 | 57 | 72 | | Sex | Male | Female | Male | | CMML type | CMML-1 | CMML-1 | CMML-2 | | IPSS | LR | INT-1 | INT-2 | | Cytogenetics | 46, XY [21] | 46, XX [20] | 46, XY [18] | | TD (TU/months) | 3 | — | 3 | | ESP treatment | + |
−
| + | | Dg.-AZA (months) | 17 | 1 | 4 | | No. of AZA cycles | 4 | 1 | 13 |
| | Counts at diagnosis | | | |
| | Hb (g/L) | 70 | 86 | 73 | | WBC (109/L) | 11.44 | 3.98 | 5.81 | | Monocytes (109/L) | 4.63 | 1.46 | 2.54 | | PLT (109/L) | 114 | 11 | 209 | | PB-blasts (%) | 0 | 5 | 11 |
| | Counts (4 AZA cycles) | | | |
| | Hb (g/L) | 85 | — | 121 | | WBC (109/L) | 6.69 | — | 6.22 | | Monocytes (109/L) | 0.68 | — | 3.03 | | PLT (109/L) | 164 | — | 126 | | PB-blasts (%) | 0 | — | 3 |
| | Comments | | | |
| | Transfusion independency (>8 weeks) | AZA-reduced, bridging treatment before ASCT → progression to AML on AZA therapy | 13 cycles of AZA → progression to AML |
|
|
AZA: 5-azacytidine (Vidaza, Celgene); IPSS: international prognostic scoring system; TD: transfusion dependency; TU: transfusion unit; ESP: erythropoiesis-stimulating protein; Hb: haemoglobin; WBC: white blood cells; PLT: platelets; PB-blasts: peripheral blood blast counts; ASCT: allogeneic stem cell transplantation.
|
